Lipoprotein(a) and PCSK9 inhibition: clinical evidence

Compelling evidence has emerged from epidemiological and Mendelian randomization analyses relative to the causality of lipoprotein(a) [Lp(a)] in atherosclerotic cardiovascular diseases (ASCVD), being elevated Lp(a) a strong risk factor regardless of the reduction of LDL-C achieved by statins. So far...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruscica, Massimiliano, Greco, Maria Francesca, Ferri, Nicola, Corsini, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673619/
https://www.ncbi.nlm.nih.gov/pubmed/33239979
http://dx.doi.org/10.1093/eurheartj/suaa135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673619/
https://www.ncbi.nlm.nih.gov/pubmed/33239979
http://dx.doi.org/10.1093/eurheartj/suaa135

Ejemplares similares